Standards of outcome reporting in surgical oncology: A case study in esophageal cancer

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4012-4018

  Blencowe, Natalie S ^a,b   McNair, Angus G K ^a,b   Davis, Christopher R ^a,b   Brookes, Sara T ^a   Blazeby, Jane M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE STUDY; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL SIGNIFICANCE; STUDY DESIGN; SYSTEMATIC REVIEW; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84876494234     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2497-x     Document Type: Review

References (22)

1. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-91. (Pubitemid 32366951)
2. Clarke M. Standardizing outcomes for trials and systematic reviews. Trials. 2007;8:39.
3. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-37. (Pubitemid 34984604)
4. Alaszewski A, Horlick-Jones T. How can doctors communicate information about risk more effectively? BMJ. 2003;327:728-31. (Pubitemid 37176758)
5. Schwartz LM, Woloshin S, Welch HG. Risk communication in clinical practice: putting cancer in context. J Natl Cancer Inst. 1999;25:124-33.
6. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2006;3:CD001556.
7. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-51. (Pubitemid 38624660)
8. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastrooesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10:754-61. (Pubitemid 40486875)
9. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538-43. (Pubitemid 36627845)
10. Polednak AP. Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98-100. (Pubitemid 36418492)
11. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928.
12. Tepper JE, Goldberg RM. An embarrassment of riches: neoad-juvant therapy of rectal cancer. J Clin Oncol. 2005;23:1339-41.
13. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-9. (Pubitemid 351265335)
14. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, et al. BladDer cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27:5680-4.
15. Lazzarino AI, Nagpal K, Bottle A, Faiz O, Moorthy K, Aylin P. Open versus minimally invasive esophagectomy: trends of utilization and associated outcomes in England. Ann Surg. 2011;252:292-8.
16. Connors RC, Reuben BC, Neumayer LA, Bull DA. Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17, 395 patients. J Am Coll Surg. 2007;205:735-40. (Pubitemid 350116630)
17. Kanaan Z, Galandiuk S, Abby M, Shannon KV, Dajani D, Hicks N, et al. The value of lesser-impact-factor surgical journals as a source of negative and inconclusive outcomes reporting. Ann Surg. 2011;253:619-23.
18. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials. 2007;8:38.
19. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.
20. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1-24.
21. Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol. 2009;99:269-72.
22. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-6. (Pubitemid 24166250)